Compositions and methods for the treatment of skin conditions
AssigneeDermata Therapeutics, Inc.
InventorsGerald Thomas PROEHL, Christopher Joseph NARDO
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the treatment of skin condition in a subject, including acne vulgaris, comprising applying to the skin of the subject a first composition comprising Spongilla, and a second composition comprising one or more fluidizing agents, such as water, saline or a hydrogen peroxide solution. The disclosure also relates to a products or kits for the treatment of skin conditions in a subject, including acne vulgaris, comprising Spongilla, and a second composition comprising one or more fluidizing agents, such as water, saline or a hydrogen peroxide solution, such as a 3% by weight solution of hydrogen peroxide.
Claims117
A method of treating acne vulgaris in a subject, comprising applying to the skin of the subject a first composition comprising Spongilla, and a second composition comprising one or more fluidizing agents.
A method for treating acne vulgaris in a subject, comprising administering to the subject a pharmaceutical composition comprising a first composition and a second composition, wherein the first composition comprises Spongilla, and the second composition comprises one or more fluidizing agents, wherein the pharmaceutical composition is applied to an area of the skin of the subject in need of treatment.
A method of treating acne vulgaris in a subject, comprising applying to an area of the skin of the subject in need of treatment a pharmaceutical composition comprising a first composition and a second composition, wherein the first composition comprises Spongilla, and the second composition comprises one or more fluidizing agents, wherein the pharmaceutical composition is applied to an area of the skin of the subject in need of treatment.
A method of treating or preventing acne vulgaris in a subject, comprising applying to an area of the skin of the subject in need of treatment a mixture comprising Spongilla and one or more fluidizing agents.
A method of reducing the number of acne vulgaris lesions on the skin of a subject, comprising applying to an area of the skin of the subject in need of treatment a mixture comprising Spongilla and one or more fluidizing agents.
A method of reducing the number of acne vulgaris lesions on the skin of a subject, comprising applying to an area of the skin of the subject in need of treatment a first composition comprising Spongilla, and a second composition comprising one or more fluidizing agents.
A method of reducing the number of acne vulgaris lesions on the skin of a subject, comprising administering to the subject a pharmaceutical composition comprising a first composition and a second composition, wherein the first composition comprises Spongilla, and the second composition comprises one or more fluidizing agents, wherein the pharmaceutical composition is applied to an area of the skin of the subject in need of treatment.
The method according to 29, wherein the subject experiences a decrease of at least one point in the subject's total score in Dermatology Life Quality Index (DLQI) following treatment with the composition compared to the subject's score in Dermatology Life Quality Index (DLQI) prior to treatment.
A kit comprising a first composition comprising Spongilla, and a second composition comprising one or more fluidizing agents.
The kit according to any one of the prior claims, wherein the first composition comprises Spongilla in the form of a powder.
The kit according to any one of the prior claims, wherein the Spongilla is in the form of a powder comprising particles that are substantially uniform in size.
The kit according to any one of the prior claims, wherein not less than 50% of the particles comprising the Spongilla powder pass through a US 70-mesh screen.
The kit according to any one of the prior claims, wherein the particles comprising the Spongilla powder have an average length of from about 50 μm to about 500 μm.
The kit according to any one of the prior claims, wherein the particles comprising the Spongilla powder have an average diameter of from about 5 μm to about 50 μm.
The kit according to any one of the prior claims, wherein the particles comprising the Spongilla powder have an aspect ratio of from about 1 to 100.
The kit according to any one of the prior claims, wherein the first composition has a residual moisture content of not more than about 10%.
The kit according to any one of the prior claims, wherein the first composition has a combined aerobic and anaerobic microbial content of not more than about 25×104 colony-forming units per gram (CFU/g).
The kit according to any one of the prior claims, wherein the first composition has a combined yeast and mold content of not more than about 25×104 colony-forming units per gram (CFU/g).
The kit according to any one of the prior claims, wherein the amount of Coliform bacteria in the first composition is not more than about 25×104 colony-forming units per gram (CFU/g).
The kit according to any one of the prior claims, wherein the amount of Salmonella in the first composition is not more than about 25×104 colony-forming units per gram (CFU/g).
The kit according to any one of the prior claims, wherein the amount of Pseudomonas aeruginosa bacteria in the first composition is not more than about 25×104 colony-forming units per gram (CFU/g).
The kit according to any one of the prior claims, wherein the amount of Staphylococcus aureus bacteria in the first composition is not more than about 25×104 colony-forming units per gram (CFU/g).
The kit according to any one of the prior claims, wherein the first composition was packaged prior to use.
The kit according to any one of the prior claims, wherein the first composition was heated to at least about 70° C. prior to being packaged.
The kit according to any one of the prior claims, wherein the first composition was heated to at least about 70° C. for at least about 5 minutes prior being packaged.
The kit according to any one of the prior claims, wherein the first composition was treated with gamma radiation prior to being packaged.
The kit according to any one of the prior claims, wherein the first composition further comprises an aqueous solution of hydrogen peroxide.
The kit according to any one of the prior claims, wherein the hydrogen peroxide is at a concentration of about 3%.
The kit according to any one of the prior claims, comprising about 2 grams of Spongilla and about 6 mL of 3% hydrogen peroxide solution.
The kit according to any one of the prior claims, wherein the Spongilla is Spongilla lacustris.
The method according to any one of the prior claims, wherein the skin of the subject is cleaned using a non-comedogenic cleanser, water, or a combination of a non-comedogenic cleanser and water following application of the first composition comprising Spongilla.
A method of treating a condition in a subject substantially as hereinbefore described with reference to any one of the Examples or described herein.
A kit substantially as hereinbefore described with reference to any one of the Examples or as described herein.
Dependencies are inferred from the claim text.